Active Biotech
0,54 SEK +1,31%Vær den første som følger denne virksomhed
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ACTI
Daglig lav / høj pris
0,518 / 0,54
SEK
Markedsværdi
195,34 mio. SEK
Aktieomsætning
41,93 t SEK
Volumen
80 t
Seneste videoer
Finanskalender
Delårsrapport
08.05.2024
Generalforsamling
22.05.2024
Delårsrapport
22.08.2024
Delårsrapport
07.11.2024
Årsrapport
13.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
MGA Holding AB | 28,1 % | 28,1 % |
Sjuenda Holding | 7,4 % | 7,4 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Annual Report 2023 Active Biotech AB (publ)
Active Biotech announces start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools